SAR-445877 is under clinical development by Sanofi and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SAR-445877’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SAR-445877 is under development for the treatment of advanced solid tumor including non-small cell lung cancer, metastatic hepatocellular carcinoma (HCC), gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma. It is administered through intravenous route in the form of solution. The drug candidate is a bi-functional fusion protein comprised of anti-PD1 antibody linked at its tail to the cytokine IL-15.
For a complete picture of SAR-445877’s drug-specific PTSR and LoA scores, buy the report here.